In bee stings, the immediate allergic reaction is clinically the most dangerous, and anaphylaxy occasionally leads to death. Empirical treatments encompass administration of antihistamines, corticosteroid hormone preparations, bronchodilators, vasopressors and anticonvulsants.
In contrast, venom immunotherapy represents a desensitization treatment for patients with stinging bee allergy. Rapid venom immunotherapy is indicated for patients with several systemic symptoms. If the kind of bee that stung the patient is known, HVE of the identified bee should be selected, unless the bee is known but cannot be specified by IgE RAST or skin test, when either yellow jacket or longlegged wasp HVE could be indicated.5 If sting by a honey bee cannot be excluded, HVE of honey bee should be used.
Venom immunotherapy can be roughly divided into 3 types : slow ; stepwise ; and rush regimens, according to differences in administration intervals. Although all types of venom immunotherapy are equally effective, rush regimen displays greater immune responses and fewer adverse reactions than slow regimen.6 Furthermore, Brehler et al. reported that ultra-rush immunotherapy, in which maintenance dose is reached in 2 days, is safer than conventional methods.7
Systemic allergic reactions during venom immunotherapy pose several problems. Sturm et al. reported freauencv of systemic allergic reaction as 0 60%.8 They noted that the wide variation among reports might be due to the different severity index of adverse effects, use of antihistamines prior to treatment, or method of administration.
With the 4-day rush regimen, frequency of systemic symptoms is about 6. 9%, lower than described in previous reports.8 In our patients, no systemic reactions developed during rapid venom immunotherapy, and local reactions at the injection site gradually disappeared. With this method, maintenance treatment for 5 years is recommended,9 as risk of systemic reactions remains at 5 -15% for 5-10 years after cessation of venom immunotherapy. Unlike the progressive decline in immunological markers with skin test and IgE levels, risk of systemic allergic reactions never decreases.10 To prospectively assess risk of recurrent systemic reaction, long-term follow-up studies are required.
The possible mechanisms of venom immunotherapy include declines in 1 ) production of specific IgE antibodies ; 2 ) activity of liberating histamines from mast cells ; 3 ) T-cell proliferation activity against specific antigen ; 4 ) production of cytokines from antigen-specific Th 1 or Th10 cells ; or 5 ) conversion Table 1 Classification of anaphylactic reaction and the number of patients from Th2 cells to Th10 or Thl cells.11 In addition, therapy may induce tolerance depending not only on specific action of venom antigens on T cells, but also on a secondary non-specific action of monocytes.12 Venom immunotherapy is covered by health insurance in various countries around the world, but not in Japan. If the treatment were to be covered in Japan, problems such as troublesome import procedures and patient expenses would be resolved. Conversely, therapy involves a risk of anaphylaxis due to injection of hymenoptera venom. Fortunately, self-administrated epinephrine became available in Japan in 2003. Establishment of standard protocols for treating stinging bee allergy is desirable.
